After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer. A range of 5-FU treatment regimens with or without biochemical modulation are currently used and toxicity appears to be schedule dependent. The use of oral 5-FU was abandoned because of erratic absorption caused by varying levels of dihydropyrimidine dehydrogenase (DPD) found in the gastrointestinal tract. This effect may be overcome by administering agents that are converted to 5-FU or by inhibiting or inactivating DPD. Xeloda® (capecitabine) was designed as an orally administered, selectively tumoractivatedTM cytotoxic agent which achieves higher levels of 5-FU in the primary tumor than in plasma or other tissues. The United States Food and Drug Administration (FDA) has approved Xeloda for use in patients with metastatic breast cancer resistant to paclitaxel and in whom further anthracycline therapy is contraindicated. Xeloda is also registered in Canada, Switzerland, Thailand and Argentina. In phase II clinical trials in colorectal cancer, Xeloda produced response rates of 21–24% and median time to disease progression of 127–230 days. Other oral agents in development for the treatment of colorectal cancer include tegafur/uracil plus oral leucovorin, S-1 and eniluracil plus oral 5-FU.

Keywords:
Colon cancer, Fluoropyrimidines, 5-FU, UFT, S-1, Xeloda® (capecitabine), Emitefur, Eniluracil, Oral chemotherapy
1.
Heidelberger C, Chandler NK, Douglas H Jr: Fluorouracil pyrimidine. A new class of tumor inhibiting compounds. Nature 1957;179:633–666.
2.
Allegra CJ, Grem JL: Antimetabolites in Cancer, Principles and Practice of Oncology, 5th ed. De Vita VT, Hellman S, Rosenberg SA (eds). Philadelphia, Lippincott-Rosen, 1997, pp 432–452.
3.
Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H Jr, Cornell G: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil – a preliminary report. Cancer 1977;39:34–40.
4.
Lokich J, Ablgren J, Guillo J, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal cancer: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425–432.
5.
The Meta-analysis Group in Cancer: Efficacy of intravenous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301–308.
6.
Hansen R, Quebberman E, Andeno T: 5-Fluorouracil by protracted venous infusion. Oncology 1989;46:245–250.
7.
Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980;40:2223–2228.
8.
Advanced Colorectal Meta-Analysis Project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896–903.
9.
Buroker TR, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailiard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14–20.
10.
Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A: Phase II study of fluorouracil (5-FU) and its modulation in advanced colorectal cancer: A Southwest Oncology Group (SWOG) Study. J Clin Oncol 1995;13:1303–1311.
11.
De Gramont A, Bosset JF, Milan C, Rougier P, Boucher O, Etienne P-E, Morvan F, Louvet C, Guillot T, François E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997;15:803–815.
12.
Wadler S, Schwartz E, Goldman M, Lyver A, Rader M, Zimmerman M, Itri I, Weinberg V, Wiernik PH: Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769–1775.
13.
Pazdur R, Abbruzzese J, Faintuch J, Ajani J, Patt Y, Jackson D, Markowitz A, Winn R, Gutterman J, Levin B: Phase II study of recombinant interferon alpha and 5-fluorouracil in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1990;9:117 (abstract 455).
14.
Kemeny N, Younes A, Secter K, Kelsen D, Sammarco P, Adams L, Derby S, Murray P, Houston C: Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 1990;66:2470–2475.
15.
Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M: Royal Marsden Phase III trial of fluorouracil with or without interferon alpha-2b in advanced colorectal cancer. J Clin Oncol 1995;13:1297–1303.
16.
Romanini A, Li WW, Colafiore JR, Bertino JR: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst 1992;84:1033–1038.
17.
Conti JA, Kemeny N, Seiter K, Goker E, Tong W, Andre M, Ragusa K, Bertino JR: Trial of sequential trimetrexate, fluorouracil and high dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994;12:695–700.
18.
Coates A, Abraham S, Kaye S, Sowerbutts T, Frewin C, Fox RM, Tattersall MH: On the receiving end – patients perceptions of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203–208.
19.
Claessen K, de Vries J, Huissman S, Dubbelman R, Van Rheenen CM, Van Dam FS, de Graaf PW: Long-term venous access with a Hickman catheter; complications and patient satisfaction. Neth J Surg 1990;42:47–49.
20.
Hoff PM, Pazdur R, Benner SE, Canetta R: UFT and leucovorin: A review of its clinical development and therapeutic potential in the oral treatment of cancer. Anti Cancer Drugs 1998;9:479–490.
21.
Liu G, Franssen E, Fitch M, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110–115.
22.
Taguchi T: Experience with UFT in Japan. Oncology 1997;11:30–34.
23.
Shirasaka T, Fujita F, Fujita M, Fukushima M, Taguchi T, Fujii S: Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice. Gan To Kagaku Ryoho 1990;17:1871–1876.
24.
Cao S, Rustum Y, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507–1510.
25.
Liu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433–5438.
26.
Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685–690.
27.
Miwa M, Ura M, Nishida N, Sawada T, Ishikawa T, Mari K, Shimma N, Umeda I, Isitsuka H: Design of a novel fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274–1281.
28.
Cao S, Lu K, Ishitsuka H, Rustum YM: Antitumor activity of capecitabine against fluorouracil sensitive and resistant tumors. Proc Am Soc Clin Oncol 1997;16:226a (abstract 795).
29.
Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16:1795–1802.
30.
Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B, Van Oosterom AT: A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumours. Clin Cancer Res 1998;4:2755–2761.
31.
Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977–2985.
32.
Schuller J, Cassidy J, Reigner B, Pietrzak C, Roos B, Springer H, Ishitsuka H, Utoh M, Dumont E: Tumor selective activation of capecitabine in colorectal cancer patients. Onkologie 1997;20:suppl 1 (abstract A732).
33.
Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Pazdur R, Verweij J: A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancers. Proc Am Soc Clin Oncol 1997;16:227a (abstract 798).
34.
Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II studies. Cancer Chemother Pharmacol 1988;22:333–338.
35.
Pazdur R, Lassere Y, Diaz-Canton E, Ho DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Cancer Invest 1998;161:145–151.
36.
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready Bl: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296–2300.
37.
Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP: A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin: An active oral regimen for advanced colorectal cancer. Cancer 1995;75:782–785.
38.
Gonzalez-Baron M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez B, Blanco E, Garcia-Giron C, Juarez F, Garrido P: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer: A phase II study. Eur J Cancer 1995;31:2215–2219.
39.
Shirasaka T, Shimamato Y, Ohsimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548–557.
40.
Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004–4009.
41.
Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito M: The oral fluorouracil prodrugs. Oncology (Huntingt) 1998;12:48–51.
42.
Peters GJ, Van Groeningen CJ, Schomage JH, Gall HE, Noordhuis P, de Vries M, Van Kullenburg A, Hanauske A-R: Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5FU)-based antineoplastic agent: Proc Am Soc Clin Oncol 1997;16:227a (abstract 800).
43.
Ohtsu A, Sakata Y, Horikoshi N, Mitachi Y, Sugimachi T, Taguchi T: Phase II study of S-1 patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998;17:262a (abstract 1005).
44.
Horikoshi N, Mitachi Y, Sakata Y, Sugimachi K, Taguchi T: S-1, new oral fluoropyrimidine, is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996;15:206 (abstract 466).
45.
Taguchi T, Horikoshi N, Kinoshita H, Toge T, Takashima S: Early phase II study of S-1 in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1996;15:121 (abstract 151).
46.
Fujii M, Kanzaki J, Satake B, Baba S, Inuyama Y: Early phase II study of S-1 in patients with advanced head and neck cancer. Proc Am Soc Clin Oncol 1996:15:316 (abstract 894).
47.
Baba H, Ohtsu A, Sakata Y, Mitachi Y, Sugimachi K, Taguchi T: Late phase II study of S-1 in patients with advanced colorectal cancer in Japan. Proc Am Soc Clin Oncol 1998;17:277a (abstract 1065).
48.
Sasaki T: New anti-cancer drugs for gastrointestinal cancers. Gan To Kagaku Ryoho 1997;24:1925–1931.
49.
Porter D, Chestnut W, Merril B, Spector T: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992;267:5236–5242.
50.
Baker S, Khor S, Adjej A, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorious SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetics, oral bioavailability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996;14:3085–3096.
51.
Baccanari D, Davis S, Knick V, Spector T: 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-FU. Proc Natl Acad Sci USA 1993;90:11064–11068.
52.
Mani S, Beck T, Chevlen E, et al: A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998;17:281A.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.